



GENERIC
PHARMASEC LTD

(Formerly Known as Adi Rasayan Limited)

CIN : L24231MH1992PLC323914



104 & 105 1st Floor Gundecha Industrial Premises Co-op Soc.
Ltd., Akurli Road, Kandivali (East) Mumbai - 400101. *



+91- 86555 50242



compliance@genpharmasec.com
info@genpharmasec.com



www.genpharmasec.com

Date: 10th February 2021

To,
The Department of Corporate Services,
Bombay Stock Exchange Limited,
14th Floor, P.J. Towers,
Dalal Street, Mumbai - 400 001.

Dear Sir/ Madam,

Subject: - Outcome of Board Meeting held on Wednesday, 10th February 2021.

Reference: BSE Scrip Code: 531592

Pursuant to the provisions of Regulation 30 (2) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform your good self that the Board of Directors of our Company in their meeting held on Wednesday, 10th February 2021 at 04.00 p.m. has:

1. Considered and approved the Un-Audited Financial Results along with Limited Review Report for the quarter ended 31st December 2020 prepared in terms of IND-AS, and Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015.

This is for your records and information.

Yours Truly,

For Generic Pharmasec Limited

Dollar
Dollar Chheda
Director
DIN: 08490484



GENERIC PHARMASEC LIMITED
(Formerly known as Adi Rasayan Limited)

Statement of Unaudited Results for the Quarter and Period Ended 31st December, 2020

(Rs. In Lakhs)

Particulars	Quarter Ended			To The Period Ended		Year Ended
	31/12/2020	30/09/2020	31/12/2019	31/12/2020	31/12/2019	31/03/2020
	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1 Revenue from Operations	241.50	388.46	248.41	1,454.66	1,079.69	1,650.13
2 Other Income	8.30	13.10	18.10	38.27	47.82	56.28
3 Total Revenue (1 + 2)	249.79	401.56	266.51	1,492.93	1,127.51	1,706.41
4 Expenses						
Cost of materials consumed	-	-	-	-	-	-
Purchase of stock-in-trade	393.05	517.74	244.29	1,521.69	777.48	1,344.64
Changes in inventories of finished goods, work-in-progress and stock-in-trade	(172.33)	(140.86)	(19.97)	4.53	237.19	179.00
Employee benefits expense	5.04	5.21	4.26	13.81	8.95	12.92
Depreciation and amortisation expense	0.33	0.29	0.14	0.91	0.34	0.49
Other expenses	21.32	24.47	9.11	62.91	30.23	48.84
Total expenses	247.41	406.85	237.83	1,603.85	1,054.18	1,585.88
5 Profit/(Loss) Before Exceptional item and Tax (3-4)	2.38	(5.29)	28.68	(110.92)	73.33	120.54
6 Exceptional items	-	-	-	-	-	-
7 Profit/(Loss) Before Tax (5-6)	2.38	(5.29)	28.68	(110.92)	73.33	120.54
8 Tax expense						
(1) Current Tax	-	13.93	18.33	-	18.33	20.00
(2) Deferred Tax	-	0.06	-	-	-	0.40
9 Profit / (Loss) from continuing operations (7 - 8)	2.38	(19.28)	10.34	(110.92)	55.00	100.14
10 Profit / (Loss) from discontinuing operations	-	-	-	-	-	-
11 Tax expense of discontinuing operations	-	-	-	-	-	-
12 Profit/(loss) from Discontinuing operations (after tax)	-	-	-	-	-	-
13 Profit (Loss) for the period (9+12)	2.38	(19.28)	10.34	(110.92)	55.00	100.14
14 Other Comprehensive income;						
A (i) Items that will not be reclassified to profit or loss	(138.60)	(88.48)	(18.44)	(170.79)	(266.13)	(358.33)
(ii) Income tax relating to items that will not be reclassified to profit or loss	-	-	-	-	-	-
B (i) Items that will be reclassified to profit or loss	-	-	-	-	-	-
(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	-
15 Total Comprehensive Income for the period (13+14) (Comprising profit/(loss) and other Comprehensive Income for the period	(136.22)	(107.77)	(8.10)	(281.72)	(211.13)	(257.40)
16 Earnings per equity share (for discontinued & continuing operations) of face value of Rs. 10 each						
(a) Basic	0.00	(0.01)	0.00	(0.04)	0.03	0.05
(b) Diluted	0.00	(0.01)	0.00	(0.04)	0.01	0.02

Notes:

- The above result were reviewed by the Audit Committee and approved by the Board Of directors at their meeting on 10th February, 2021. In terms of SEBI circular CIR/CFD/CMD/56/2016 dated 28th May, 2016, the Company declares that the statutory auditors have issued Audit Report with an unmodified opinion.
- The above result have been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS), prescribed under section 133 of the Companies Act 2013, and other recognized accounting practices and policies to the extent applicable.
- The company has reported segment information as per the Indian Accounting Standard 108 "Operating Segments" (IND AS 108) in "Annexure-I".
- Previous period figures have been regrouped/reclassified as considered necessary to facilitate comparison.



For and on behalf of the Board of
GENERIC PHARMASEC LIMITED
(Formerly known as Adi Rasayan Limited)

Dollar
(DOLLAR AZAD CHHEDA)
DIRECTOR
DIN: 08490484

PLACE: MUMBAI
DATE: 10.02.2021

GENERIC PHARMASEC LIMITED
(Formerly known as Adi Rasayan Limited)

"ANNEXURE - I"

Statement of Unaudited Segment-wise Revenue, Results, Assets and Liabilities for the Quarter and Period Ended 31st December, 2020

Particulars	Quarter Ended			To The Period Ended		Year Ended
	31/12/2020	30/09/2020	31/12/2019	31/12/2020	31/12/2019	31/03/2020
	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
Segment Revenue						
Pharmaceuticals	222.26	388.46	248.41	1,435.42	1,079.69	1,650.13
Trading in Securities	19.24	-	-	19.24	-	-
Total Revenue	241.50	388.46	248.41	1,454.66	1,079.69	1,650.13
Segment Results (Profit before tax and interest)						
Pharmaceuticals	16.42	43.31	20.27	116.62	52.11	108.63
Trading in Securities	(0.74)	-	-	(0.74)	-	-
Total	15.68	43.31	20.27	115.88	52.11	108.63
Less						
(i) Unallocated Finance Cost	-	-	-	-	-	-
(ii) Other unallocable expenditure net of unallocable income	13.30	48.60	(8.40)	226.80	(21.22)	(11.90)
(iii) Inter Segment Eliminations	-	-	-	-	-	-
Profit Before Tax	2.38	(5.29)	28.68	(110.92)	73.33	120.54
Segment Assets						
Pharmaceuticals	837.67	996.05	1,000.89	837.67	1,000.89	1,047.43
Trading in Securities	296.18	-	-	296.18	-	-
Un-Allocated	1,454.36	3,042.79	1,630.23	1,454.36	1,630.23	1,439.57
Total	2,588.21	4,038.83	2,631.12	2,588.21	2,631.12	2,487.00
Segment Liabilities						
Pharmaceuticals	294.48	605.47	306.45	294.48	306.45	553.40
Trading in Securities	-	-	-	-	-	-
Un-Allocated	2,293.73	3,433.36	2,324.67	2,293.73	2,324.67	1,933.60
Total	2,588.21	4,038.83	2,631.12	2,588.21	2,631.12	2,487.00

The company has reported segment information as per the Indian Accounting Standard 108 "Operating Segments" (IND AS 108)

For and on behalf of the Board of
GENERIC PHARMASEC LIMITED
(Formerly known as Adi Rasayan Limited)



Dollar
(DOLLAR AZAD CHHEDA)

DIRECTOR
DIN : 08490484

PLACE : MUMBAI
DATE : 10.02.2021



Limited Review Report on Standalone Financial Result

To
Board of Directors of
GENERIC PHARMASEC LIMITED

We have reviewed the accompanying statement of unaudited financial results of **GENERIC PHARMASEC LIMITED** for the quarter ended 31st December, 2020 and year to date results for the period from 1st April, 2020 to 31st December, 2020 ('the Statement') attached herewith, being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

This statement is the responsibility of the Company's Management and has been approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013, read with Rule 3 of Companies (Indian Accounting Standards) Rule, 2015, as amended and other accounting principles generally accepted in India. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited standalone financial results prepared in accordance with applicable accounting standards i.e. Indian accounting Standards ('Ind AS') prescribed under s.133 of the Companies Act, 2013 read with relevant rules issued there under and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For ABHISHEK S TIWARI & ASSOCIATES

Chartered Accountants

Firm Reg.No.141048W




ABHISHEK TIWARI

Partner

M.No.155947

Place: Mumbai

Date: 10.02.2021

UDIN: **21155947AAAAAT1811**